Revenue decline in the drug discovery support business due to delays in starting clinical trials and fewer orders for preclinical studies
First written in FY2024-Q1. 3 of 10 entries say "Restated". Latest entry: 2026-08-06.
1 other company's latest entry also says "Mitigated".
- 2026-08-06MitigatedEarnings
「The CRO business increased revenue due to higher orders in both the clinical-trial and nonclinical businesses in the previous fiscal year, as well as the completion of a large-scale safety study in the nonclinical business and other factors.」
The CRO business increased revenue due to higher orders in the clinical-trial and nonclinical businesses and other factors, demonstrating improvement from the factors that had previously contributed to the decline in revenue. - FY2026WorsenedAnnual report
「The CRO business posted lower revenue due to a decline in clinical trial orders caused by the impact of the inappropriate matter involving LSIM, among other factors, as well as the completion of a large-scale safety study in the nonclinical business in the same period of the previous year.」
In addition to the previous factors of delays in starting clinical trials and fewer orders for nonclinical studies, a decline in clinical trial orders due to the impact of the inappropriate matter involving LSIM was identified as a factor behind the CRO business's lower full-year revenue. - 2026-05-13WorsenedEarnings
「The CRO business recorded a decline in revenue due to a decrease in clinical-trial orders resulting from the impact of the inappropriate incident involving LSIM and other factors, as well as the completion of a large-scale safety study in the nonclinical business in the same period of the previous year.」
The decline in CRO revenue was attributed to the reaction to the completion of a large-scale safety study in the previous period, in addition to a decrease in clinical-trial orders resulting from the inappropriate incident involving LSIM. - FY2026-H1ReframedAnnual report
「The CRO business posted lower revenue because a large-scale safety study had been completed in the nonclinical business in the same period of the previous year.」
The explanation of factors behind lower revenue in the drug discovery support business changed from the previous reasons of delays in starting clinical trials and fewer orders for nonclinical studies to the negative comparison effect of a large-scale safety study completed in the same period of the previous year. - FY2025RestatedAnnual report
「The CRO business declined slightly year on year, as the contribution from winning a large-scale project in the nonclinical business was outweighed by lower revenue in the clinical trial business.」
Although the nonclinical business won a large-scale project, revenue in the clinical trial business continued to decline, and the CRO business decreased slightly for the full fiscal year. - FY2025-H1MitigatedAnnual report
「The CRO business posted higher revenue, mainly due to the completion of a large-scale safety study in the nonclinical business.」
The completion of a large-scale safety study in the nonclinical business emerged as a factor supporting higher revenue in the drug discovery support business, which had previously cited delays in starting clinical trials and fewer orders for nonclinical studies. - FY2024RestatedAnnual report
「The drug discovery support business posted higher revenue in the fourth quarter of the current fiscal year due to an increase in large-scale projects, but revenue declined slightly for the full fiscal year.」
While the effects of delays in starting clinical trials and fewer orders for nonclinical studies remained for the full fiscal year, revenue also increased in the fourth quarter due to an increase in large-scale projects. - FY2024-Q3RestatedAnnual report
「In the LSIM business's clinical testing operations, the number of routine tests increased, but revenue declined due to the decrease in PCR testing volumes accompanying the reclassification of COVID-19 from the equivalent of Category 2 to Category 5, among other factors, as well as delays in starting clinical trials and lower orders for nonclinical studies in the drug discovery support business.」
Delays in starting clinical trials and fewer orders for nonclinical studies continued and were again identified as factors behind lower revenue in the LSIM business. - FY2024-Q2MaterialisedAnnual report
「Other factors behind lower revenue included the impact of delays in starting clinical trials and fewer orders for nonclinical studies in the drug discovery support business.」
Delays in starting clinical trials and fewer orders for nonclinical studies continued to be reflected as factors behind lower revenue in the LSIM business during the current fiscal year. - FY2024-Q1First statedAnnual report
「The drug discovery support business posted lower revenue year on year due to delays in starting clinical trials and fewer orders for nonclinical studies.」
Delays in starting clinical trials and fewer orders for nonclinical studies became apparent as factors behind lower revenue in the drug discovery support business.